Lexicon Q2 Update: SONATA-HCM Enrollment Complete, ZYNQUISTA NDA Resubmission Set for Q4 2026
LXRX has more than doubled off its 52-week low of $1.02.
Summary
Lexicon's Q2 2026 update provides several incremental catalysts. The pivotal Phase 3 SONATA-HCM study for sotagliflozin in hypertrophic cardiomyopathy has completed enrollment, exceeding the 500-patient target, with top-line data still expected in Q1 2027. The company now expects to resubmit the ZYNQUISTA NDA for type 1 diabetes in Q4 2026, based on safety data from the STENO1 trial. Additionally, Novo Nordisk's Phase 1 study of LX9851 for obesity is ongoing, with completion expected in Q1 2027. Viatris has secured regulatory approvals for sotagliflozin in heart failure in UAE and Bahrain, with submissions in multiple other markets. Lexicon reported a Q2 net loss, though no specific financial figures were highlighted.
At the time of this announcement, LXRX was trading at $2.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $1.02 to $2.68. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.